Arcellx, Inc.
ACLX
Clasificación en acciones
#2786
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Precio por acción
$115.07
Última sincronización: 2026-05-15
Capitalización bursátil
$6.73B
Cambio (1 día)
0.00%
Cambio (1 año)
32.61%
País
US
Comercio Arcellx, Inc. (ACLX)
Categoría
Healthcare
Ratio P/B de Arcellx, Inc. (ACLX)
Ratio P/B al October 2026 TTM: 16.10
Según los informes financieros más recientes y el precio de las acciones de Arcellx, Inc., el ratio P/B actual (TTM) es 16.10. Al final de 2023, el ratio P/B era 5.50.
Historial del ratio P/B de Arcellx, Inc. desde 2018 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 16.10 | 78.33% |
| 2024 | 9.03 | 64.37% |
| 2023 | 5.50 | -17.57% |
| 2022 | 6.67 | 32.34% |
| 2021 | 5.04 | -30.41% |
| 2020 | 7.24 | -140.56% |
| 2019 | -17.85 | -9,055.54% |
| 2018 | 0.20 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -61.18% |
US
|
|
| 13.2547 | -17.69% |
US
|
|
| 4.208 | -73.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -61.61% |
NL
|
